Will the COVID-19 drug Paxlovid be reimbursed in H1 2024?

By Lee, Tak-Sun | translator Kim, Jung-Ju

24.04.16 06:43:39

가나다라 0

KDCA pushes for its reimbursement as part of Korea’s general healthcare system

After the company applied for the reimbursement in October of the past year, the agenda was not presented to DREC until April this year

Receives 3rd request for supplementary data...reimbursement by June unclear even if the company proceeds with pricing negotiations in May

Whether the reimbursement of the COVID-19 drug Paxlovid (nirmatrelvir and ritonavir, Pfizer), which the government has been working to make part of Korea’s general healthcare system after the end of the COVID-19 pandemic, will be able to be listed within the originally planned date is gaining attention.

The Korea Disease Control and Prevention Agency aimed to list the drug within the first half of this year, but in the current situation, it appears that the authorities may miss the target date.

According to industry sources on the 15th, the Health Insurance Reimbursement and Assessment Service requested a supplemental response letter for Paxlovid to Pfizer.

As a result, P

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)